Patent: 10,093,732
✉ Email this page to a colleague
Summary for Patent: 10,093,732
| Title: | Antagonists of IL-6 to prevent or treat thrombosis |
| Abstract: | The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al. |
| Inventor(s): | Smith; Jeffrey T. L. (Bellevue, WA) |
| Assignee: | ALDERBIO HOLDINGS LLC (Las Vegas, NV) |
| Application Number: | 14/933,141 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,093,732
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Bausch Health Us, Llc | IPRIVASK | desirudin | For Injection | 021271 | 04/04/2003 | ⤷ Try a Trial | 2028-11-25 |
| Janssen Biotech, Inc. | REOPRO | abciximab | Injection | 103575 | 12/22/1994 | ⤷ Try a Trial | 2028-11-25 |
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2028-11-25 |
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2028-11-25 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
